Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

77 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Synergistic effects of combined Wnt/KRAS inhibition in colorectal cancer cells.
Mologni L, Brussolo S, Ceccon M, Gambacorti-Passerini C. Mologni L, et al. Among authors: ceccon m. PLoS One. 2012;7(12):e51449. doi: 10.1371/journal.pone.0051449. Epub 2012 Dec 5. PLoS One. 2012. PMID: 23227266 Free PMC article.
In vitro and in vivo identification of ABCB1 as an efflux transporter of bosutinib.
Redaelli S, Perini P, Ceccon M, Piazza R, Rigolio R, Mauri M, Boschelli F, Giannoudis A, Gambacorti-Passerini C. Redaelli S, et al. Among authors: ceccon m. J Hematol Oncol. 2015 Jul 7;8:81. doi: 10.1186/s13045-015-0179-4. J Hematol Oncol. 2015. PMID: 26149173 Free PMC article.
Synergistic activity of ALK and mTOR inhibitors for the treatment of NPM-ALK positive lymphoma.
Redaelli S, Ceccon M, Antolini L, Rigolio R, Pirola A, Peronaci M, Gambacorti-Passerini C, Mologni L. Redaelli S, et al. Among authors: ceccon m. Oncotarget. 2016 Nov 8;7(45):72886-72897. doi: 10.18632/oncotarget.12128. Oncotarget. 2016. PMID: 27662658 Free PMC article.
Mitochondrial Hyperactivation and Enhanced ROS Production are Involved in Toxicity Induced by Oncogenic Kinases Over-Signaling.
Ceccon M, Mauri M, Massimino L, Giudici G, Piazza R, Gambacorti-Passerini C, Mologni L. Ceccon M, et al. Cancers (Basel). 2018 Dec 12;10(12):509. doi: 10.3390/cancers10120509. Cancers (Basel). 2018. PMID: 30545064 Free PMC article.
Lorlatinib Treatment Elicits Multiple On- and Off-Target Mechanisms of Resistance in ALK-Driven Cancer.
Redaelli S, Ceccon M, Zappa M, Sharma GG, Mastini C, Mauri M, Nigoghossian M, Massimino L, Cordani N, Farina F, Piazza R, Gambacorti-Passerini C, Mologni L. Redaelli S, et al. Among authors: ceccon m. Cancer Res. 2018 Dec 15;78(24):6866-6880. doi: 10.1158/0008-5472.CAN-18-1867. Epub 2018 Oct 15. Cancer Res. 2018. PMID: 30322862 Free article.
Ceritinib as a promising therapy for ALK related diseases.
Ceccon M. Ceccon M. Transl Lung Cancer Res. 2014 Dec;3(6):376-8. doi: 10.3978/j.issn.2218-6751.2014.08.09. Transl Lung Cancer Res. 2014. PMID: 25806325 Free PMC article.
NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922.
Mologni L, Ceccon M, Pirola A, Chiriano G, Piazza R, Scapozza L, Gambacorti-Passerini C. Mologni L, et al. Among authors: ceccon m. Oncotarget. 2015 Mar 20;6(8):5720-34. doi: 10.18632/oncotarget.3122. Oncotarget. 2015. PMID: 25749034 Free PMC article.
Crizotinib-resistant NPM-ALK mutants confer differential sensitivity to unrelated Alk inhibitors.
Ceccon M, Mologni L, Bisson W, Scapozza L, Gambacorti-Passerini C. Ceccon M, et al. Mol Cancer Res. 2013 Feb;11(2):122-32. doi: 10.1158/1541-7786.MCR-12-0569. Epub 2012 Dec 13. Mol Cancer Res. 2013. PMID: 23239810
Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors.
Redaelli S, Mologni L, Rostagno R, Piazza R, Magistroni V, Ceccon M, Viltadi M, Flynn D, Gambacorti-Passerini C. Redaelli S, et al. Among authors: ceccon m. Am J Hematol. 2012 Nov;87(11):E125-8. doi: 10.1002/ajh.23338. Epub 2012 Oct 9. Am J Hematol. 2012. PMID: 23044928
Colorectal tumors are effectively eradicated by combined inhibition of {beta}-catenin, KRAS, and the oncogenic transcription factor ITF2.
Mologni L, Dekhil H, Ceccon M, Purgante S, Lan C, Cleris L, Magistroni V, Formelli F, Gambacorti-Passerini CB. Mologni L, et al. Among authors: ceccon m. Cancer Res. 2010 Sep 15;70(18):7253-63. doi: 10.1158/0008-5472.CAN-10-1108. Epub 2010 Sep 7. Cancer Res. 2010. PMID: 20823162
77 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback